Immunic, Inc. Common Stock
$10.12
-$0.25 (-2.41%)
$10.03Day Range$10.63
Key Statistics
Market Cap
$138.08M
Shares Outstanding
13.6M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Apr 17, 2014
Round Lot
100
Locale
US
Trading Data
Day Open
$10.50
Day High
$10.63
Day Low
$10.03
Volume
229.3K
VWAP
$10.26
Prev Close
$10.37
Transactions
--
Acc. Volume
--
About Immunic, Inc. Common Stock
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
PHARMACEUTICAL PREPARATIONSSIC 283495 employees1200 AVENUE OF THE AMERICAS, NEW YORK, X1, 10036(332) 255-9818IPO Apr 17, 2014US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001280776
- Composite FIGI
- BBG001M75SX4
- Share Class FIGI
- BBG001V10N36
- Ticker Root
- IMUX
- SIC Code
- 2834
About Immunic, Inc. Common Stock (IMUX) Stock
Immunic, Inc. Common Stock (IMUX) closed the 2026-09-16 session at $10.12, down 2.41% versus the previous close (-0.25). The stock opened at $10.50 and traded between $10.03 and $10.63 during that session. Session trading volume was 229K shares. The volume-weighted average price (VWAP) is $10.26.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
Immunic, Inc. Common Stock has a market capitalization of $138.1 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. IMUX is listed on the XNAS exchange. The company employs approximately 95 people. Immunic, Inc. Common Stock is headquartered in NEW YORK, X1. The recorded listing date is 2014-04-17.
On this page you can find market IMUX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.